Questions about COVID-19?

What Patients & Families Need to Know | New Visitor Policy | Guidance for Community Healthcare Providers

A photo of Ashish Kumar.

Director, Langerhans Cell Histiocytosis Center

Director, Hematology/Oncology Fellowship Program

Professor, UC Department of Pediatrics

513-636-7287

513-803-1969

Board Certified

Best Doctors logo

My Biography & Research

Biography

Dr. Kumar received his medical degree from L.T.M. Medical College, Mumbai, India, his PhD in anatomy and cell biology from the University of Iowa, pediatric residency training at the Mayo Clinic and fellowship in pediatric hematology / oncology / BMT at the University of Minnesota. He is currently a professor of pediatrics at the University of Cincinnati College of Medicine in the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's Hospital Medical center. Dr. Kumar’s laboratory research has focused on infant leukemia, and Langerhans Cell Histiocytosis. He is the director of the LCH center, and a key member of the HLH center at Cincinnati Children’s. He is also the director of pediatric hematology-oncology fellowship training program.

Visit the HLH Center of Excellence.

Learn more about the 700 Miles to Hope Bike Ride.

Dr. Kumar has been elected by peers for inclusion in the Best Doctors in America List.

Additional Languages

Hindi

Clinical Interests

Childhood cancer and blood disorders; immune deficiency

Research Interests

Leukemia biology; cancer biology

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, Langerhans Cell Histiocytosis, Rasopathy, Hemophagocytic lymphohistiocytosisHLH, Experimental Hematology and Cancer Biology, Bone Marrow Transplantation, Cancer and Blood Diseases

Cincinnati Children's Blog

A Ride For HLH Research

BlogRare and Complex Conditions

A Ride For HLH Research

By Ashish Kumar, MD, PhD1/17/2019

A Message from Dr Kumar Learn about HLH Become a Donor

BlogRare and Complex Conditions

A Message from Dr. Kumar – Learn about HLH, Become a Donor

By Ashish Kumar, MD, PhD9/23/2016

My Locations

My Education

MD: LTM Medical College, Mumbai, India.

Residency: Mayo Clinic, Rochester, MN.

Fellowship: University of Minnesota, Minneapolis, MN.

PhD: University of Iowa, Iowa City, IA.

Certification: General Pediatrics; Pediatric Hematology/Oncology Subspecialty.

Licenses: State of Ohio; State of Minnesota.

My Publications

Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Jordan, MB; Allen, CE; Greenberg, J; Henry, M; Hermiston, ML; Kumar, A; Hines, M; Eckstein, O; Ladisch, S; Nichols, KE; et al. Pediatric Blood and Cancer. 2019; 66.

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. La Rosee, P; Horne, A; Hines, M; Greenwood, TV B; Machowicz, R; Berliner, N; Birndt, S; Gil-Herrera, J; Girschikofsky, M; Jordan, MB; et al. Blood. 2019; 133:2465-2477.

Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Gurunathan, A; Boucher, AA; Mark, M; Prus, KM; O'Brien, MM; Breese, EH; Mizukawa, BE; Absalon, MJ; Nelson, AS; Jordan, MB; et al. Pediatric Blood and Cancer. 2018; 65:e27400-e27400.

Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Eckstein, O; McAtee, CL; Greenberg, J; Kumar, A; Fein-Levy, C; Smith, T; Tran, B; McClain, KL. Pediatric Hematology-Oncology (Informa). 2018; 35:427-433.

Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis. Lucchini, G; Marsh, R; Gilmour, K; Worth, A; Nademi, Z; Rao, A; Booth, C; Amrolia, P; Silva, J; Chiesa, R; et al. Blood. 2018; 132:2088-2096.

Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Rotz, SJ; Ware, RE; Kumar, A. Pediatric Blood and Cancer. 2018; 65:e27260-e27260.

Partial growth hormone insensitivity and dysregulatory immune disease associated with de novo germline activating STAT3 mutations. Gutierrez, M; Scaglia, P; Keselman, A; Martucci, L; Karabatas, L; Domene, S; Martin, A; Pennisi, P; Blanco, M; Sanguineti, N; et al. Molecular and Cellular Endocrinology. 2018; 473:166-177.

CNS Langerhans Cell Histiocytosis: Common Hematopoietic Origin for LCH-Associated Neurodegeneration and Mass Lesions. McClain, KL; Picarsic, J; Chakraborty, R; Zinn, D; Lin, H; Abhyankar, H; Scull, B; Shih, A; Lim, KP H; Eckstein, O; et al. Cancer. 2018; 124:2607-2620.

Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Kumar, B; Garcia, M; Weng, L; Jung, X; Murakami, JL; Hu, X; McDonald, T; Lin, A; Kumar, AR; DiGiusto, DL; et al. Leukemia. 2018; 32:575-587.

Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Hashem, H; Kumar, AR; Mueller, I; Babor, F; Bredius, R; Dalal, J; Hsu, AP; Holland, SM; Hickstein, DD; Jolles, S; et al. Blood. 2017; 130:2682-2688.